Necitumumab is a monoclonal antibody used to treat metastatic squamous non-small cell lung cancer. It functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant progression.
- Mechanism
- Curator reviewed
Necitumumab is an EGFR antagonist that functions by binding to epidermal growth factor receptor (EGFR) and preventing binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant progression. Binding of necitumumab to EGFR induces receptor internalization and degradation.
- Primary indication
- Necitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC).Curator reviewed · 1 structured indication
- First approval
- Canada, 2017 · United States, 2015
- Code names
- IMC-11F8
Resolves to
What you can answer from here — as of September 20, 2026
Which drugs share a target with Necitumumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account